Cyclo Therapeutics Stock Performance
| CYTHW Stock | USD 0.13 0.01 7.14% |
Cyclo Therapeutics holds a performance score of 6 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.92, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Cyclo Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Cyclo Therapeutics is expected to outperform it slightly. Use Cyclo Therapeutics jensen alpha and the relationship between the potential upside and price action indicator , to analyze future returns on Cyclo Therapeutics.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Cyclo Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly conflicting technical indicators, Cyclo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Strattan Ce Rick of 8209 shares of Cyclo Therapeutics subject to Rule 16b-3 | 09/17/2024 |
2 | Disposition of tradable shares by Wong Vivien of Cyclo Therapeutics subject to Rule 16b-3 | 10/01/2024 |
3 | Acquisition by Toig Randall M. of 3350 shares of Cyclo Therapeutics at 1.28 subject to Rule 16b-3 | 11/18/2024 |
4 | Cyclo Therapeutics, Inc. Reports Q3 Loss, Lags Revenue Estimates - MSN | 11/20/2024 |
5 | SHAREHOLDER ALERT The MA Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH - The Eastern Progress Online | 12/10/2024 |
| Begin Period Cash Flow | 1.5 M | |
| Free Cash Flow | -16.2 M |
Cyclo |
Cyclo Therapeutics Relative Risk vs. Return Landscape
If you would invest 13.00 in Cyclo Therapeutics on September 13, 2024 and sell it today you would earn a total of 0.00 from holding Cyclo Therapeutics or generate 0.0% return on investment over 90 days. Cyclo Therapeutics is currently producing 1.7065% returns and takes up 19.3184% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Cyclo, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cyclo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cyclo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cyclo Therapeutics, and traders can use it to determine the average amount a Cyclo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0883
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CYTHW | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 19.32 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.71 actual daily | 34 66% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Cyclo Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyclo Therapeutics by adding it to a well-diversified portfolio.
Cyclo Therapeutics Fundamentals Growth
Cyclo Stock prices reflect investors' perceptions of the future prospects and financial health of Cyclo Therapeutics, and Cyclo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cyclo Stock performance.
| Return On Equity | -226.64 | ||||
| Return On Asset | -2.82 | ||||
| Operating Margin | (45.78) % | ||||
| Revenue | 1.08 M | ||||
| EBITDA | (20.03 M) | ||||
| Net Income | (20.06 M) | ||||
| Cash And Equivalents | 2.24 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.03 M | ||||
| Current Ratio | 0.87 X | ||||
| Book Value Per Share | 0.17 X | ||||
| Cash Flow From Operations | (16.19 M) | ||||
| Market Capitalization | 62.76 M | ||||
| Total Asset | 13.25 M | ||||
| Retained Earnings | (83.86 M) | ||||
| Working Capital | 3.85 M | ||||
About Cyclo Therapeutics Performance
Evaluating Cyclo Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cyclo Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cyclo Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 942.92 | 542.51 | |
| Return On Tangible Assets | (1.51) | (1.44) | |
| Return On Capital Employed | (4.20) | (4.40) | |
| Return On Assets | (1.51) | (1.44) | |
| Return On Equity | (4.22) | (4.43) |
Things to note about Cyclo Therapeutics performance evaluation
Checking the ongoing alerts about Cyclo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cyclo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cyclo Therapeutics is way too risky over 90 days horizon | |
| Cyclo Therapeutics has some characteristics of a very speculative penny stock | |
| Cyclo Therapeutics appears to be risky and price may revert if volatility continues | |
| Cyclo Therapeutics has accumulated 1.03 M in total debt. Cyclo Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Cyclo Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 1.08 M. Net Loss for the year was (20.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cyclo Therapeutics has accumulated about 2.24 M in cash with (16.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cyclo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: SHAREHOLDER ALERT The MA Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH - The Eastern Progress Online |
- Analyzing Cyclo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cyclo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cyclo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cyclo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cyclo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cyclo Therapeutics' stock. These opinions can provide insight into Cyclo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.